|Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013|
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
|Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015|
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
|Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98|
AS Coates, A Keshaviah, B Thurlimann, H Mouridsen, L Mauriac, ...
Journal of clinical oncology 25 (5), 486-492, 2007
|Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …|
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
|Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial|
V Galimberti, BF Cole, S Zurrida, G Viale, A Luini, P Veronesi, P Baratella, ...
The lancet oncology 14 (4), 297-305, 2013
|Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen|
M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ...
Journal of Clinical Oncology 28 (3), 509-518, 2010
|Adjuvant exemestane with ovarian suppression in premenopausal breast cancer|
O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ...
New England Journal of Medicine 371 (2), 107-118, 2014
|Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials|
Early Breast Cancer Trialists' Collaborative Group
The Lancet 386 (10001), 1341-1352, 2015
|De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017|
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
|Adjuvant ovarian suppression in premenopausal breast cancer|
PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ...
New England Journal of Medicine 372 (5), 436-446, 2015
|Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels|
M Colleoni, A Rocca, MT Sandri, L Zorzino, G Masci, F Nole, G Peruzzotti, ...
Annals of Oncology 13 (1), 73-80, 2002
|Very young women (< 35 years) with operable breast cancer: features of disease at presentation|
M Colleoni, N Rotmensz, C Robertson, L Orlando, G Viale, G Renne, ...
Annals of Oncology 13 (2), 273-279, 2002
|Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents|
Y Shaked, E Henke, JML Roodhart, P Mancuso, MHG Langenberg, ...
Cancer cell 14 (3), 263-273, 2008
|Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment|
M Colleoni, G Viale, D Zahrieh, G Pruneri, O Gentilini, P Veronesi, ...
Clinical Cancer Research 10 (19), 6622-6628, 2004
|Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006|
M Kaufmann, G Von Minckwitz, HD Bear, A Buzdar, P McGale, H Bonnefoi, ...
Annals of Oncology 18 (12), 1927-1934, 2007
|International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?|
O Pagani, E Senkus, W Wood, M Colleoni, T Cufer, S Kyriakides, A Costa, ...
Journal of the National Cancer Institute 102 (7), 456-463, 2010
|Depression and degree of acceptance of adjuvant cytotoxic drugs|
M Colleoni, M Mandala, G Peruzzotti, C Robertson, A Bredart, ...
The Lancet 356 (9238), 1326-1327, 2000
|Overall survival with palbociclib and fulvestrant in advanced breast cancer|
NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ...
New England journal of medicine 379 (20), 1926-1936, 2018
|Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial|
D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ...
The Lancet Oncology 19 (7), 904-915, 2018
|Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer|
S Dellapasqua, F Bertolini, V Bagnardi, E Campagnoli, E Scarano, ...
Journal of Clinical Oncology 26 (30), 4899-4905, 2008